Wiseguyreports.Com Adds “Cognition and Memory Enhancement Drugs -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025” To Its Research Database
Increasing use of cognition drugs is the major factor that drives the global cognition and memoryenhancing drugs market. Cognition drugs play a crucial role in the treatment of cognitively impaired patients. Neurodegeneration is the major concern faced by people in various regions of the world, and it is also the major factor responsible causing severe diseases in such patients. The intensification and rise in research and development is expected to drive growth of the cognition and memory-enhancing drugs market.
The market is observing various launches of new products and improvement in existing technologies. The existing as well as new technologies are expected to increase the demand for cognition and memory-enhancing drugs in the market. However, the major restricting aspect of the global cognition and memory-enhancing drugs market is the longer timelines associated with the cognition drugs. Ensuring efficacy as well as safety during use of cognition drugs will aid in overcoming the threat of adverse effects.
In this report, the cognition and memory-enhancing drugs market is studied through different perspectives. The market is analyzed through the products and their applications in the treatment of several chronic diseases.
The cognition and memory-enhancing drugs market is categorized into eight types based on products: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs.
The Namenda cognition drug registered a revenue of REDACTED in 2016 and is poised to increase at a compound annual growth rate (CAGR) of REDACTED throughout the forecast period; this revenue is projected to reach REDACTED by 2022. Demand for Namenda is significant in the treatment of cognitively impaired patients. Additionally, this drug has gained immense traction in recent years among the youth.
The global cognition and memory-enhancing drugs market based on applications is segmented in four categories: Alzheimer’s disease, education industry, sports, and other applications. The Alzheimer’s disease segment has dominated the global cognition and memory-enhancing drugs market and is anticipated to do so during the forecast period.
This segment accounted for a revenue of REDACTED in 2016, registering a CAGR of REDACTED; this revenue is expected to reach REDACTED by 2022. However, the use of cognition products in sports applications has increased in recent years. The sports sector has registered a CAGR of REDACTED, indicating a rapid growth among all the other applications.
By geography, the global cognition and memory-enhancing drugs market is divided into North America, Europe, Asia-Pacific, and the Rest of World (ROW). North America held the largest market share in 2016 and accounted for REDACTED, growing at the CAGR of REDACTED during the analysis period. It is anticipated that market will reach REDACTED by 2022. In North America, the U.S. leads the market due to surging demand for cognition products as well as memory enhancers in the treatment of Alzheimer’s disease. Asia-Pacific held the second-largest market share for the cognition and memory-enhancing drugs market globally; it accounted for REDACTED in 2016 and is expected to reach REDACTED by 2022 at a CAGR of REDACTED. Japan is leading the cognition and memory-enhancing drugs market in the Asia-Pacific region, and the growth of this market is supplemented by increasing government initiatives to encourage production of cognition drugs as well as focusing on brain fitness. Asia-Pacific is a lucrative market for cognition drugs. The majority of the markets in Asia-Pacific and ROW regions are untapped and hence provide opportunities for cognition drugs manufacturers to expand their business.Report Scope
This research report presents an in-depth analysis of the global cognition and memory-enhancing drugs market by application, product categories, and regional markets. The report includes key cognition drugs that are incorporated in several therapeutic treatment methods. It discusses the role of supply chain members from manufacturers to researchers. The report has an in-depth analysis of key companies operating in the global cognition and memory-enhancing drugs market. In-depth patent analysis in the report will focus on providing extensive technological trends across years and regions such as the U.S., Europe, and China.
The cognition and memory-enhancing drugs market is segmented mainly into eight components: Aricept, Exelon, Reminyl, Namenda, Adderall, Ritalin, Dexedrin, and other cognition drugs. This market is further segmented on the basis of applications, which helps in understanding the potency of these memory enhancers in several therapeutic treatments. The market study is detailed for products based on applications as well as its further implication on the research and development area. These two segmentations are also discussed in detail for the given period. The market is segmented by region into the North America, Europe, Asia-Pacific, and ROW. Companies profiled in this report include Pfizer, Novartis, Shire Pharmaceuticals, Allergan plc, Barr Pharmaceuticals, and Cephalon.
– 34 data tables and 14 additional tables
– An overview of the global market for cognition and memory enhancement drugs
– Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
– An overview of the ethics and side effects of cognition and memory enhancement drugs
– Market analyses by application, product, and region
– Assessment of patent litigation claims
– Insight into the competitive landscape, including mergers and acquisitions and new product launches
– Profiles of key companies in the market, including
- ALLERGAN PLC
- ALTERNASCRIPT LLC
- CAMBRIDGE COGNITION
- COGNITION THERAPEUTICS INC.
- COGSTATE LTD.
- NOVARTIS AG
- ONNIT LABS LLC
- PEAK NOOTROPICS
- PFIZER INC.
- PURELIFE BIOSCIENCE CO., LTD.
- SUPNOOTROPIC BIO CO., LTD.
- TEVA PHARMACEUTICALS INDUSTRIES LTD. (BARR PHARMACEUTICALS)
Contact Us: Sales@Wiseguyreports.com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)